# Immunogenicity of Hepatitis A Vaccine in Inflammatory Bowel Disease (IBD) Patients

> **NCT01341808** · PHASE4 · COMPLETED · sponsor: **Asan Medical Center** · enrollment: 493 (actual)

## Conditions studied

- Inflammatory Bowel Disease
- Crohn's Disease
- Ulcerative Colitis
- Hepatitis A

## Interventions

- **BIOLOGICAL:** Epaxal Berna (virosomal hepatitis A vaccine)

## Key facts

- **NCT ID:** NCT01341808
- **Lead sponsor:** Asan Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04
- **Primary completion:** 2013-02
- **Final completion:** 2013-03
- **Target enrollment:** 493 (ACTUAL)
- **Last updated:** 2013-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01341808

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01341808, "Immunogenicity of Hepatitis A Vaccine in Inflammatory Bowel Disease (IBD) Patients". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01341808. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*